BenevolentAl Therapeutics Pipeline and Triage
Growing number of platform-generated programmes
moving into clinical phases
Disease Area
Atopic Dermatitis (PanTrk inhibitor)
Ulcerative Colitis (PDE10 Inhibitor)
Amyotrophic Lateral Sclerosis
Inflammatory Bowel Disease
Glioblastoma Multiforme
CNS Diseases
Nonalcoholic Steatohepatitis (NASH)
Oncology
Antiviral
Nonalcoholic Steatohepatitis (NASH)
Oncology
Oncology
Chronic Kidney Disease
Idiopathic Pulmonary Fibrosis
10+ Early Discovery Programmes
(Multiple indications & targets in therapy
areas such as Oncology, Immunology, CNS,
GI, Metabolic Disorders and Others)
Target ID
Hit to Lead
Lead Opt
Preclinical
Clinical
Commercial
AstraZeneca
AstraZeneca
Phase I start
in early 2023
Highlights
• All Pipeline assets generated
from Benevolent Platform™M
Broad therapy area coverage
given disease agnostic
approach
Mix of Best in class, First in
class and novel indications
Potential for rapid scaling and
expansion into new modalities
Existing pipeline alone addresses prevalent
patient base* of >263m (1) and current
market opportunity >$30bn (2)
Source: (1) GlobalData, Epidemiology forecasts 2021, Atopic Dermatitis (7MM), IBD (8MM), ALS (8MM), GBM (7MM), NASH (7MM), CKD (7MM), IPF (7MM); 7MM = 7 major
markets (US, JP, EU5); 8MM = US, JP, EU5+ Canada; (2) Evaluate Pharma, Current Worldwide Market Size (data pull 22nd Sept 2021) Atopic Dermatitis, IBD, ALS, GBM,
NASH, CKD, IPF
ΑΙ
Benevolent 37View entire presentation